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Abstract
Purpose Vogt–Koyanagi–Harada (VKH) disease is
a primary autoimmune granulomatous choroiditis that
begins in the choroidal stroma. The aim of this review
was to gather a body of evidence for the concept of a
window of therapeutic opportunity, defined as a time
interval following initial-onset disease during which
adequate treatment will substantially modify the
disease outcome and possibly even lead to cure,
similar to what has been described for rheumatoid
arthritis.
Methods We reviewed the literature and consulted
leading experts in VKH disease to determine the
consensus for the notion of a therapeutic window of
opportunity in VKH disease.
Results We found a substantial body of evidence in
the literature that a therapeutic window of opportunity
exists for initial-onset acute uveitis associated with
VKH disease. The disease outcome can be
C. P. Herbort Jr. (&)
Retinal and Inflammatory Eye Diseases, Centre for
Ophthalmic Specialized Care (COS), Clinic Montchoisi
Teaching Centre, Rue Charles-Monnard 6,
1003 Lausanne, Switzerland
e-mail: cph@herbortuveitis.ch
C. P. Herbort Jr.
Department of Ophthalmology, University of Lausanne,
Lausanne, Switzerland
A. M. Abu El Asrar (&)
Department of Ophthalmology and Dr. Nasser Al-Rashid
Research Chair in Ophthalmology, College of Medicine,
King Saud University, Riyadh, Saudi Arabia
e-mail: abuelasrar@yahoo.com
M. Takeuchi
Department of Ophthalmology, National Defence Medical
College, Tokorozawa, Saitama, Japan
C. E. Pavésio
National Institute for Health Research, Biomedical
Research Centre at Moorfields Eye Hospital, NHS
Foundation Trust and UCL, Institute of Ophthalmology,
London, UK
C. Couto
Department of Ophthalmology, University of Buenos
Aires, Buenos Aires, Argentina
A. Hedayatfar
Noor Eye Hospital and Rassoul Akram Hospital, Iran
University of Medical Sciences, Tehran, Iran
K. Maruyama
Department of Innovative Visual Science, Graduate
School of Medicine, Osaka University, Osaka, Japan
X. Rao
Department of Ophthalmology, General Police Hospital,
University of Chile, Santiago, Chile
123
Int Ophthalmol (2019) 39:1419–1425
https://doi.org/10.1007/s10792-018-0949-4
substantially improved if dual systemic steroidal and
non-steroidal immunosuppressants are given within
2–3 weeks of the onset of initial VKH disease,
avoiding evolution to chronic disease and develop-
ment of ‘‘sunset glow fundus.’’ Several studies addi-
tionally report series in which the disease could be
cured, using such an approach.
Conclusions There is substantial evidence for a
therapeutic window of opportunity in initial-onset
acute VKH disease. Timely and adequate treatment
led to substantial improvement of disease outcome and
prevented chronic evolution and ‘‘sunset glow fun-
dus,’’ and very early treatment led to the cure after
discontinuation of therapy in several series, likely due
to the fact that the choroid is the sole origin of
inflammation in VKH disease.
Keywords Vogt–Koyanagi–Harada disease 
Therapeutic window of opportunity stromal
choroiditis  Autoimmune disease  Indocyanine green
angiography  Immunosuppressive therapy  Sunset
glow fundus
A window of opportunity is a brief time interval during
which a suitable action will achieve success. Once this
period passes, the window is closed and the desired
outcome is no longer achievable. The therapeutic
window of opportunity is a well-established concept of
critical importance in medicine, specifically for
rheumatoid arthritis (RA), and considerable attention
has been paid to its timing [1]. In a case–control study,
Nell et al. [2] showed that there was a window of
opportunity for highly successful RA treatment in the
first year, especially within the first 3 months of
therapy, and they suggested that early diagnosis and
therapy is a crucial step toward achieving optimal
control of RA progression and prognosis. This window
represents a very early disease phase in which
therapeutic disease modification is more successful,
likely because the underlying disease process is not
fully matured. A growing body of evidence has
emphasized the consistent clinical and radiographic
benefits of prompt initiation of disease-modifying
anti-rheumatic drugs (DMARDs) for patients with
rheumatoid arthritis during the early stages of the
disease. Therapeutic intervention during this period
alters disease progression in such a way that chronicity
is reduced, resulting in a greater proportion of patients
in drug-free remission after treatment withdrawal as
well as reduced mortality. These findings have led to
changes in rheumatoid arthritis treatment paradigms,
with an increasing emphasis on early diagnosis and
treatment [3, 4].
Timely and appropriate therapeutic intervention
may substantially modify the outcome of ocular
inflammatory disorders in a similar way.
This may have important consequences for the care
of initial-onset acute uveitis associated with Vogt–
Koyanagi–Harada (VKH) disease, as delivering the
right therapies at the right time could reduce the
burden of the disease and substantially alter the
outcome. VKH pathogenesis in the eye is character-
ized by an autoimmune reaction against stromal
melanocytes or associated proteins [5–8]. It is consid-
ered a primary stromal choroiditis because the
inflammatory reaction electively starts within the
choroidal stroma [9]. The initial-onset acute disease
typically exhibits granulomatous choroiditis with
exudative retinal detachment and optic disk hyperemia
and swelling, followed by anterior segment involve-
ment and eventual development into chronic recurrent
granulomatous anterior uveitis if not properly treated,
with typical ‘‘sunset glow fundus’’ (SGF) and chori-
oretinal atrophy [10–13].
Ocular involvement is limited to subclinical occult
choroiditis during the prodromal phase of initial-onset
disease. Acute clinically apparent ocular disease
develops after choroiditis spills over into the neigh-
boring structures. This early stage of disease repre-
sents the therapeutic window of opportunity, during
which the disease is amenable to appropriate thera-
peutic intervention. If the window closes without
sufficient treatment, evolution will irremediably pro-
gress toward chronic disease (smoldering or recurrent)
which is much more refractory to treatment and needs
prolonged and repeated therapeutic intervention [12].
Chronic disease resulting from improper treatment
must be distinguished from initial-onset disease which
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may be substantially impacted by treatment and
susceptible to long-term remission and even cure.
Intraocular inflammation in insufficiently treated
VKH disease will proceed to recurrent granulomatous
anterior and posterior uveitis and typical sunset glow
fundus (SGF), even when systemic monotherapy is
given early in disease [10–16].
Therefore, we must consider both the time interval
for the window of opportunity, and what is appropriate
therapy for the treatment of initial-onset VKH disease.
The exact timing of the therapeutic window is
difficult to determine, but it is clear that the earlier
appropriate therapy begins, the higher the chances to
achieve an optimal outcome. One study defined the
therapeutic window as 2 weeks following disease
onset [17]. Although each patient is different, it is
accurate to conclude that the window of therapeutic
opportunity closes approximately 2–3 weeks after
initial onset [17]. Immediate use of non-steroidal
immunosuppression has the advantage to result in
immediate inflammation suppressive activity if imme-
diately acting agents such as cyclosporine are used. If
agents with delayed activity are used, such as
mycophenolic acid, it results in efficient activity at
the needed time when corticosteroid tapering has
started.
Fortunately, much more precise information is
available about the appropriate therapy for initial-
onset VKH disease.
Corticosteroid monotherapy has been shown to be
inappropriate even if given within an adequate
timeframe
Convincing evidence has become available so far to be
able to say that systemic corticosteroid monotherapy is
not sufficient even if given at an early stage of disease
to prevent chronic evolution. A recent publication
reported a high percentage of clinical recurrence in
VKH patients given early high-dose corticosteroids
with slow taper, as 79% of patients progressed to
chronic recurrent disease and 38% developed subreti-
nal fibrosis [18]. Additional studies by Chee et al. [19],
and Keino et al. [20], showed that steroid monotherapy
given at initial-onset disease was incapable of pre-
venting chronic evolution, which is significantly
associated with more severe anterior segment inflam-
mation, has a worse visual acuity [12], a worse mean
retinal sensitivity [21] and more frequent complica-
tions compared with initial-onset acute VKH disease
receiving appropriate therapy [11, 12, 21]. Moreover,
it was shown that chronic recurrent disease was far
more refractory to treatment [21].
The result of chronic ongoing inflammation of the
choroid is SGF, which indicates insufficient therapy.
Keino et al. [22] followed 102 patients with VKH
disease from initial onset who were treated with high-
dose corticosteroid therapy. SGF developed in 67.6%
of patients, and the mean duration before SGF
appearance was 4.2 ± 2.7 months. Lai et al. [23]
similarly demonstrated SGF development in 51.4% of
patients who received oral corticosteroids during their
first attack of VKH disease. These data represent
substantial evidence indicating that systemic corticos-
teroid monotherapy cannot control progressive sub-
clinical choroidal inflammation in most cases, even
when given shortly after onset of the disease.
Combination of steroidal and non-steroidal
immunosuppression is required to treat initial-
onset acute VKH disease in order to prevent
chronic evolution
Because numerous studies have shown that corticos-
teroid monotherapy is insufficient to prevent chronic
evolution, combinations of corticosteroids with first-
line non-steroidal immunosuppressive therapies such
as cyclosporine, azathioprine, mycophenolate mofetil,
anti-tumor necrosis factor-a agents, or others have
been proposed to achieve better control of the uveitis,
facilitate earlier tapering of corticosteroids, and avoid
chronic evolution in acute initial-onset disease
[17, 24–27]. First-line immunosuppression is defined
here as the initiation of immunosuppression at the
onset of disease concomitant to corticosteroids and not
thereafter, as is the case in most studies speaking of
first-line immunosuppressive therapy.
Subclinical choroiditis is the reason for chronic
evolution and is clearly identified by ICGA, uncover-
ing active choroidal inflammation in an apparently
quiescent eye during follow-up while monitoring
corticosteroid tapering [28–33]. This shows that the
standard corticosteroid monotherapy is indeed sup-
pressing clinically apparent disease, but is insufficient
to suppress choroidal inflammation [32]. Subclinical
evolution of choroidal inflammation has also been
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clearly documented by several groups investigating
smoldering disease with the help of ICGA [28–33],
explaining that the development of SGF despite
corticosteroid therapy results from the progressive
loss of stromal melanocytes due to the ongoing
insufficiently controlled immunological process
[19, 32]. This is a strong incentive to maintain
sufficiently dosed therapy including first-line non-
steroidal immunosuppressive drugs, even in the sub-
acute phase and during the corticosteroid tapering
process, to be sure to eradicate choroidal inflammation
[24–33]. An Indian group proposed early and high-
dose triple agent immunosuppression in 2006 and
reported favorable outcomes with disease remission in
all five reported patients [34].
Association of steroidal and non-steroidal
immunosuppression induces long-term remission
and even cure of VKH disease
Abu El-Asrar et al. [24] determined the effectiveness
of mycophenolate mofetil (Cellcept) combined with
systemic corticosteroids as first-line therapy for very
early initial-onset acute VKH disease without AC
inflammatory signs [26]. They compared the outcomes
in this group with those of a group of patients with
acute VKH uveitis treated with corticosteroid
monotherapy or with the previously reported delayed
addition of immunomodulatory therapy [35]. The use
of Cellcept as first-line therapy combined with
systemic corticosteroids was safe and effective in the
treatment of acute uveitis associated with VKH
disease, and significantly reduced the development
of chronic recurrent inflammation and late complica-
tions and also improved visual outcome. None of the
patients developed SGF, suggesting that it was also
effective in controlling progressive subclinical chor-
oidal inflammation. Mycophenolate mofetil was also
effective in preventing the development of vitiligo,
poliosis, alopecia, and sensory hearing loss [24, 26]. In
a series [26] of 38 patients with initial-onset acute
uveitis associated with VKH disease, 22 (57.9%)
patients were able to discontinue treatment without
relapse of inflammation. The median durations of
corticosteroid therapy and mycophenolate mofetil
therapy in these patients were 17.5 and 20.2 months,
respectively, and the patients were off treatment for a
median period of 25.5 months.
Another study compared medium-dose corticos-
teroid monotherapy to high-dose corticosteroid ther-
apy combined with non-steroidal immunosuppression
and showed that all patients in the corticosteroid
monotherapy group showed SGF after 4 months.
ICGA also showed the persistence of numerous
hypofluorescent dark dots (HDDs) in the corticos-
teroid group, while no patient showed SGF nor HDDs
in the combined group [32].
In a series of 9 VKH patients receiving combined
steroidal and non-steroidal immunosuppression with
ICGA assisted monitoring of therapy to detect
subclinical recurrence of choroiditis, a high proportion
(7/9, 78%) of cases ‘‘healed’’ with no recurrent activity
within a mean follow-up therapy-free period of
26 ± 14.8 months, and a low proportion of cases
developed SGF (3/9, 33%) [29]. However, the mean
duration of treatment was 27.3 months ± 38.2
months (range 9–114), much longer than the
6–9 months typically recommended in the literature
[29]. These results indicate that early, combined,
sustained, and if possible ICGA-monitored treatment
is able to modify the VKH disease phenotype,
avoiding SGF and achieving cure, much in the same
fashion as early and sustained therapy changes the
phenotype of birdshot retinochoroiditis [36]. Treat-
ment duration is variable and individually different,
depending on the time-point of treatment initiation,
disease severity, and individual susceptibility to
treatment, which may include biomarkers indicating
therapy response in the future [37]. Treatment should
not be stopped if subclinical ICGA-detected choroidi-
tis remains present, and the duration should be
15 months at minimum, and ideally closer to
24 months [29].
Initial-onset acute VKH, a condition particularly
prone to benefit from the concept of therapeutic
window of opportunity
The particularity of initial-onset acute VKH is that
inflammation develops exclusively within the choroid,
meaning that intraocular inflammation completely
subsides once choroiditis is completely under control,
as there is no other origin of inflammation. However,
we know by now that all choroidal inflammation may
not be silenced even when clinically apparent disease
appears to be under control. ICGA monitoring of VKH
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patients under treatment has shown that choroidal
inflammation is still present in most cases once clinical
signs as well as morphological and functional param-
eters have normalized [28–33, 38–40], and the persis-
tence of this choroidal subclinical disease explains the
evolution toward SGF in most insufficiently treated
cases [20, 22, 41].
Zero tolerance to choroiditis must therefore be the
aim if cure of the disease is to be achieved. Some
authors proposed ICGA monitoring for regression of
choroidal disease in the convalescent phase of disease
and long-term tapering of therapy until absence of
recurrence of choroidal subclinical disease, i.e.,
absence of recurrence of hypofluorescent dark dots
(HDDs) on ICGA [29]. Ideally, if possible and
available to the clinician, meaningful ICGA monitor-
ing presupposes an ICGA every 5–6 weeks during the
first 4–6 months and then every 2–3 months during
the long-term tapering period [29]. Performing an
ICGA every 6 months in the follow-up of VKH
disease does not allow for timely treatment modifica-
tion, but is nevertheless useful in order to provide
information about the presence or absence of subclin-
ical occult choroiditis [42]. ICGA is very reactive and
precise for evaluating disease activity in the choroid
and allows for therapy readjustment and safe tapering
[43]. The treatment durations reported in textbooks or
in published literature are not long enough to achieve
zero tolerance of choroiditis and safe withdrawal of
treatment [29, 44]. With optimal management includ-
ing early combined steroidal and first-line non-
steroidal immunosuppression, SGF should not be
considered part of the natural course of the disease,
but rather the result of insufficient treatment that failed
to stop subclinical choroidal inflammation [45]. In
contrast to many reports, a recent report stated that
corticosteroid therapy in initial-onset disease was
sufficient to achieve a satisfactory outcome with non-
steroidal immunosuppression necessary in only 15.3%
of cases [46]. No information was given, however, on
the rate of clinical chronic evolution, nor on occult
chronic evolution as ICGA was not performed. No
information was given either on treatment-free follow-
up. Sunset glow fundus was reported at the rate of
close to 50%, anterior and posterior recurrence at the
rate of 22.5% and complications at the rate of 21.2%.
Judging by these numbers, chronic evolution must not
have been negligible.
Perspective: the therapeutic window
of opportunity in VKH
In summary, VKH disease is a primary stromal
choroiditis with inflammation initiating exclusively
from the choroid, the structure that should be targeted
by therapy. The choroidal compartment is easily
accessible to systemic therapy, unlike the retina. There
is increasing evidence that a substantial proportion of
cases can be cured before depigmentation occurs if
treatment is conducted with a zero tolerance for
recurrence of the mostly subclinical choroiditis that
can be detected by ICGA, Three crucial conditions
must be satisfied to achieve this goal: (1) early therapy
initiation, given that the therapeutic window is likely
the 2–3 first weeks following disease onset, (2) a
combination of steroidal and first-line non-steroidal
immunosuppression, and (3) zero tolerance to sub-
clinical choroiditis, best monitored by ICGA with the
need to re-increase therapy if HDDs are still present or
reappear.
The disease will evolve toward chronic VKH in the
absence of such a strict approach within an appropriate
time period, a disease differentiated from initial-onset
VKH and more resistant to therapy, not prone to
remission, and often leading to ocular (SGF, subretinal
fibrosis, glaucoma) and extra-ocular complications
including integumentary changes (vitiligo, alopecia,
poliosis) and hearing loss.
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